Currently out of the existing stock ratings of Brian Cheng, 91 are a BUY (80.53%), 5 are a SELL (4.42%), 17 are a HOLD (15.04%).

Brian Cheng

Work Performance Price Targets & Ratings Chart

Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 46.49% that have a potential upside of 23.03% achieved within 106 days.

Brian Cheng’s has documented 212 price targets and ratings displayed on 28 stocks. The coverage is on Healthcare, Utilities sectors.

Most recent stock forecast was given on XNCR, Xencor at 03-Sep-2026.

Wall Street Analyst Brian Cheng

Analyst best performing recommendations are on CRGX (CARGO THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 3/4/2025. The price target of $57 was fulfilled within 7 days with a profit of $18.34 (47.44%) receiving and performance score of 67.77.

Average potential price target upside

of $122.55 (83.02%) on ACET (ADICET BIO).
of $16.5 (98.26%) on IMVT (IMMUNOVANT ).
of $15.72 (15.48%) on BPMC (BLUEPRINT MEDICINES CORP).

ARCT Arcturus Therapeutics Holdings PSTX Poseida Therapeutics ADCT ADC Therapeutics SA IMNM Immunome SRRA Sierra Oncology GOSS Gossamer Bio APLS Apellis Pharmaceuticals NTLA Intellia Therapeutics ROIV Roivant Sciences Ltd XNCR Xencor ACET Adicet Bio BCAB Bioatla ALLO Allogene Therapeutics MRSN Mersana Therapeutics PTGX Protagonist Therapeutics ZYME Zymeworks Common Stock BPMC Blueprint Medicines Corp EDIT Editas Medicine IMVT Immunovant CRGX CARGO Therapeutics, Common Stock KYTX Kyverna Therapeutics, Common Stock ITOS Iteos Therapeutics PGEN Precigen BCRX BioCryst Pharmaceuticals CGON CG Oncology, Common stock MGX Metagenomi, Common Stock RGLS Regulus Therapeutics SR Spire

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Mayank Mamtani (B. RILEY)

Hold Since 18-Mar-2026

$22

$6.18 (39.06%)

$23

5 months 23 days ago
(18-Mar-2026)

6/7 (85.71%)

$15.45 (235.88%)

Whitney Ijem (CANACCORD)

Buy Since 07-Feb-2020

$21

$5.18 (32.74%)

6 months 5 days ago
(05-Mar-2026)

1/7 (14.29%)

$13.75 (189.66%)

Yasmeen Rahimi (PIPER SANDLER)

Buy Since 04-Mar-2020

$25

$9.18 (58.03%)

6 months 6 days ago
(04-Mar-2026)

5/14 (35.71%)

$17.42 (229.82%)

Yigal Nochomovitz (CITI)

Hold Since 13-Nov-2025

$-7.82 (-49.43%)

6 months 6 days ago
(04-Mar-2026)

7/12 (58.33%)

$0.42 (5.54%)

142

Andrew Fein (HC WAINWRIGHT)

Hold Since 12-Nov-2025

$-6.82 (-43.11%)

9 months 29 days ago
(12-Nov-2025)

1/2 (50%)

$0.87 (10.70%)

175

Show more analysts

Please expand the browser size to see the chart

Which stock is Brian Cheng most bullish on?

Potential upside of $21.33 has been obtained for CGON (CG ONCOLOGY, COMMON STOCK)

Which stock is Brian Cheng most reserved on?

Potential downside of -$39.72 has been obtained for PTGX (PROTAGONIST THERAPEUTICS)

What Year was the first public recommendation made by Brian Cheng?

On 2019